Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $62.5 million.

  • Harvard Bioscience's Total Non-Current Liabilities fell 303.5% to $62.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.5 million, marking a year-over-year decrease of 303.5%. This contributed to the annual value of $62.0 million for FY2024, which is 122.1% down from last year.
  • According to the latest figures from Q3 2025, Harvard Bioscience's Total Non-Current Liabilities is $62.5 million, which was down 303.5% from $62.9 million recorded in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's Total Non-Current Liabilities peaked at $81.1 million during Q1 2022, and registered a low of $60.1 million during Q2 2024.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $66.5 million (2023), whereas its average is $68.6 million.
  • Per our database at Business Quant, Harvard Bioscience's Total Non-Current Liabilities soared by 1372.64% in 2022 and then crashed by 1407.35% in 2023.
  • Quarter analysis of 5 years shows Harvard Bioscience's Total Non-Current Liabilities stood at $78.5 million in 2021, then decreased by 8.06% to $72.1 million in 2022, then dropped by 12.92% to $62.8 million in 2023, then decreased by 1.22% to $62.0 million in 2024, then grew by 0.66% to $62.5 million in 2025.
  • Its last three reported values are $62.5 million in Q3 2025, $62.9 million for Q2 2025, and $63.6 million during Q1 2025.